NEW YORK, Sept. 25, 2012 /PRNewswire/ -- IntraLinks® (NYSE: IL), a leading, global technology provider of inter-enterprise content management and collaboration solutions, today announced that Actelion Pharmaceuticals Ltd, an Allschwil/ Basel, Switzerland headquartered biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments to serve unmet medical needs, has selected IntraLinks Connect(SM) to streamline their documentation exchange during clinical trials.
Prior to engaging IntraLinks, Actelion relied on traditional courier services to facilitate the exchange of sensitive clinical trial documentation between sponsors and participants, resulting in excessive shipping costs and manual processes for tracking and other activities.
To streamline their documentation process and gain efficiency for themselves and their investigators, Actelion chose IntraLinks Connect to provide central clinical trial portals to facilitate the more secure, compliant auditable exchange of site feasibility, study start up, study conduct and study close-out documentation.IntraLinks Connect's security, detailed reporting, workflows, and analytics, together with IntraLinks' knowledgeable professional service support convinced Actelion that IntraLinks provided the best fit to their requirements. "Whilst working with IntraLinks we can see the maturity of their technology and the commitment of the team to support Actelion moving forward in this area," said Christine Schwenninger, Head of Global Clinical Monitoring, Actelion. "We are looking forward to working closely together with IntraLinks in the coming years." "Actelion's engagement of IntraLinks demonstrates the growing demand for secure information exchange within the clinical trial process," says Andy Watson, VP of life sciences EMEA at IntraLinks. "IntraLinks Connect will provide Actelion greater efficiency, traceability, and security to improve communication, collaboration, and document exchange between everyone involved in the clinical trial." About IntraLinks IntraLinks Holdings, Inc. (NYSE: IL) is a leading, global technology provider of inter-enterprise content management and collaboration solutions. Through innovative Software-as-a-Service solutions, IntraLinks solutions are designed to enable the exchange, control, and management of information between organizations securely and compliantly when working through the firewall. More than 2 million professionals at 800 of the Fortune 1000 companies depend on IntraLinks' experience. With a track record of enabling high-stakes transactions and business collaborations valued at more than $19 trillion, IntraLinks is a trusted provider of easy-to-use, enterprise strength, cloud-based collaboration solutions. For more information, visit www.intralinks.com. About Actelion Ltd. Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/ Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,500 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®) . For more information, visit www.actelion.com. Forward Looking Statements The forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are all express or implied statements that are not based on historical information and include, among other things, statements concerning IntraLinks' plans, intentions, expectations, projections, hopes, beliefs, objectives, goals and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control and could cause actual results to differ materially from those contemplated in these forward-looking statements. Accordingly, there can be no assurance that the results expressed, projected or implied by any forward-looking statements will be achieved, and readers are cautioned not to place undue reliance on any forward-looking statements. The forward-looking statements in this press release speak only as of the date hereof. As such, IntraLinks undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For a detailed list of the factors and risks that could affect IntraLinks' financial results, please refer to IntraLinks public filings with the Securities and Exchange Commission (the "SEC") from time to time, including its Annual Report on Form 10-K for the year-ended December 31, 2011 and subsequent reports. Trademarks and Copyright IntraLinks®, IntraLinks Exchange(SM), IntraLinks Designer(SM), IntraLinks Courier(SM), IntraLinks Dealspace(SM), IntraLinks Connect(SM), Extended Enterprise ™ and other trademarks and service marks of IntraLinks appearing in this press release are the property of IntraLinks, Inc. This press release may also refer to trade names and trademarks of other organizations without reference to their status as registered trademarks. © 2012. All rights reserved. SOURCE IntraLinks Holdings, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV